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Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is a relatively common condition which results in a
mortality of up to 33%. Up to 40% of infants treated with nitric oxide (iNO) either have a transient response or fail
to demonstrate an improvement in oxygenation. Milrinone, a selective phosphodiesterase 3 (PDE3) inhibitor with
inotropic and lusitropic properties may have potential benefit in PPHN. This pilot study was developed to assess the
impact of milrinone administration on time spent on iNO in infants with PPHN. This is a multicentre, randomized,
double-blind, two arm pilot study, with a balanced (1:1) allocation of 20 infants. In this pilot study, we hypothesise
that infants ≥34 weeks gestation and ≥ 2000 g with a clinical and echocardiography diagnosis of PPHN, intravenous
milrinone used in conjunction with iNO will result in a reduction in the time spent on iNO. In addition, we hypothesise
that milrinone treatment will lead to an improvement in myocardial performance and global hemodynamics when
compared to iNO alone. We will also compare the rate of adverse events associated with the milrinone, and the
pre-discharge outcomes of both groups. The purpose of this pilot study is to assess the feasibility of performing
the trial and to obtain preliminary data to calculate a sample size for a definitive multi-centre trial of milrinone
therapy in PPHN.
Trial registration: www.isrctn.com; ISRCTN:12949496; EudraCT Number:2014–002988-16.
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Introduction
Scope of the problem
Persistent pulmonary hypertension of the newborn
(PPHN) is a relatively common condition occurring in
0.5 to 7 per 1000 live births and results in a mortality
ranging between 4 to 33% [1, 2]. Inhaled nitric oxide
(iNO) and extracorporeal membrane oxygenation (ECMO)
are the only current therapeutic options that are systematic-
ally evaluated in clinical trials [3, 4]. The vasodilatation in-
duced by iNO is mediated by increasing concentrations of
the second messengers: cyclic guanyl monophosphate
(cGMP) and cyclic adenosine monophosphate (cAMP) in
pulmonary vascular smooth muscle. The widespread use of
iNO has resulted in a reduction in the need for ECMO;
however, mortality and long-term morbidity remain un-
changed [1, 4]. In addition, up to 40% of infants treated
with iNO either have a transient response or fail to demon-
strate an improvement in oxygenation [4, 5]. iNO does not
improve myocardial performance in infants with PPHN,
which often accompanies the condition and may contribute
to mortality. Furthermore, the increasing cost of adminis-
tering iNO to infants with PPHN may prohibit its use in
developing countries. Due to these challenges, there is a
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real need to evaluate novel approaches to the management
of PPHN.
Pathophysiology and clinical characteristics of PPHN
The condition is clinically characterised by hypoxemic
respiratory failure due to the lack of transition of the
pulmonary vasculature from a high resistance fetal to a
low resistance extra uterine circuit. Pulmonary vascular
resistance (PVR) remains high resulting in right to left
shunting across the patent foramen ovale (PFO) and the
patent ductus arteriosus (PDA) resulting in hypoxemia.
On a cellular level, the condition is characterised by
marked endothelial dysfunction, with an excess of vaso-
constrictor substances (phosphorylated myosin light chains
(MLC-P), endothelin 1 (ET-1) and reactive nitrogen
species) over vasodilator compounds (cGMP, cAMP, and
myosin light chain phosphatase (MLCP)) [6, 7]. Chronic ex-
posure to hypoxia may lead to pulmonary vessel wall thick-
ening with increased connective tissue deposition and neo-
muscularisation. This results in a more permanent vascular
change termed pulmonary vascular remodelling [8].
Myocardial dysfunction associated with PPHN
Right (RV) and left (LV) ventricular function may be
compromised in PPHN as a result of increased RV afterload
and reduced LV preload (due to the reduced pulmonary
venous return) [9]. The effects of a pressure-loaded, dilated
right heart include a shift in the interventricular septum
and compression of the left ventricle, both resulting in de-
creased LV filling and hence cardiac LV output (LVO). The
low cardiac output state resulting from reduced LV preload
can lead to a fall in blood pressure in infants with PPHN
necessitating the use of vasoactive inotropes such as dopa-
mine and adrenaline. Animal data suggest that these ino-
tropes raise systemic and pulmonary vascular resistance
and may further contribute to RV compromise in the set-
ting of PPHN [10, 11]. Several studies have demonstrated
the association of a low cardiac output in the setting of
PPHN with morbidity and mortality [12–14].
The potential use of milrinone in PPHN
Cyclic nucleotide phosphodiesterases (PDE) are a family
of enzymes that hydrolyse the phosphodiester bond in
cAMP and cGMP thereby inhibiting their pulmonary
vasodilator properties. Two isoforms, PDE3 and PDE5
are abundantly present in the neonatal lung and play a
key role in the pathogenesis of PPHN [15]. PDE3 has a
predominant hydrolysing effect on cAMP. Milrinone is a
selective PDE3 inhibitor with pharmacological effects in-
cluding relaxation of vascular smooth muscle, enhanced
myocardial contractility (inotropy) and improved myocar-
dial relaxation (lusitropy) [16, 17]. In the newborn lamb,
intravenous milrinone augments the action of prostaglan-
dins (PGI2) on pulmonary vasculature by significantly
shortening the onset and prolonging the duration and de-
gree of pulmonary vasodilation produced by PGI2 [18, 19].
Milrinone may also exhibit synergistic effects with iNO in
lowering PVR [20, 21].
The use of milrinone is established in neonates and
children following cardiac surgery for the prevention of
low cardiac output syndrome and the treatment of pul-
monary hypertension [22, 23]. Its use in the setting of
PPHN of the newborn is limited to case series demon-
strating an improvement in oxygenation when used in
infants with PPHN failing to respond to iNO [24, 25].
Through its lusitropic and inotropic properties, milri-
none may be an effective agent in addressing RV and LV
dysfunction in the setting of PPHN.
Lack of consensus in the management of PPHN
Despite recent advances in the management of PPHN,
the risk of mortality and adverse neurological sequelae
remains high and often prompt neonatologists to institute
additional therapies. However, there is no consensus on
the choice of therapeutic interventions in addition to iNO.
Characterizing variation in practices is a crucial step
toward improved patient outcome. As a result, our group
conducted a prospective cross-sectional online survey
of neonatologists to evaluate intensive care practices in
Canada and the Australia-New Zealand region (AUS-NZ).
A 35-item questionnaire was developed, validated, and
piloted to collect information on diagnosis, inhaled nitric
oxide (iNO) practices, alternative vasodilators or cardio-
tropes, and echocardiography. Variation among survey
respondents as well as intergroup comparison was per-
formed. Data were collected from 217 respondents. Echo-
cardiography and arterial blood gas were the most common
diagnostic tests used to assess the severity of PPHN. iNO
administration was more frequently scrutinized in Canada
(36% versus 10% [AUS-NZ], p < 0.001) due to the higher
cost of the therapy in North America. As a consequence,
Canadian neonatologists reported higher use of intravenous
milrinone (p < 0.001), vasopressin (p= 0.02), and inhaled
prostacyclin (p= 0.02), but lower use of sildenafil (p= 0.01)
for refractory pulmonary hypertension. A greater proportion
of neonatologists in AUS-NZ were trained to perform echo-
cardiography (p < 0.001) to optimize treatment decisions. As
a result of this wide variation in the management of PPHN,
there is a need to provide more guidance regarding princi-
ples of management while recognizing the dynamic nature
of cardiopulmonary physiology in individual patients [26].
Pharmacokinetics of milrinone in PPHN
The pharmacological profile of milrinone in persistent
pulmonary hypertension of the newborn, its short term
outcomes and safety profile was recently delineated by
our group in an open label prospective pharmacological
study of 11 neonates with PPHN [27]. The study included
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infants ≥34 weeks gestation with birth weights ≥1500 g;
less than 10 days old and within 24 h of admission; echo-
cardiography diagnosis of PPHN [right to left shunt at
PFO or PDA level and/or severe tricuspid regurgitation];
absence of congenital heart disease and an indwelling
arterial line. The most common reasons for PPHN were
meconium aspiration syndrome and hypoxic-ischemic
encephalopathy. The median ages at administration of
iNO and milrinone were 7.5 h (range 4–22) and 14 h
(range 10–30); therefore, the interval between these
co-treatments was a median of 7 h (4.5–16). All pa-
tients required 100% oxygen prior to administration of
iNO. There was no interval improvement in median
oxygen requirement (100% vs. 98% [86–100], p = 0.35)
or oxygenation index (37.2 ± 9.0 vs. 41.6 ± 21.6, p =
0.53) after iNO administration (prior to initiation of
milrinone).
Infants received an intravenous loading dose of milri-
none (50 μg/kg) over 60 min followed by a maintenance
infusion (0.33–0.99 μg/kg/min) for 24–72 h. Serial blood
milrinone levels were collected after the bolus, following
initiation of the maintenance infusion to determine
steady state levels, and following discontinuation of the
drug to determine clearance. Echocardiography was per-
formed before and after (1, 12 h) milrinone initiation. The
mean (SD) gestational age and weight at birth were 39.2 ±
1.3 weeks and 3481 ± 603 g. The median dose and duration
of milrinone following the bolus were 0.33 μg/kg/min
(range 0.33–0.99 μg/kg/min) and 24 h (range 24 to 42 h).
The mean (SD) half-life, total body clearance, volume of
distribution, and steady state concentration of milrinone
were 4.1 ± 1.1 h, 0.11 ± 0.01 L/kg/hour, 0.56 ± 0.19 L/kg,
and 290.9 ± 77.7 ng/ml.
The initiation of milrinone led to an improvement in
PaO2 (p = 0.002) and a sustained reduction in FiO2 (p <
0.001), oxygenation index (p < 0.001), mean airway pres-
sure (p = 0.03), and inhaled nitric oxide dose (p < 0.001).
Although a transient reduction in systolic arterial pressure
(p < 0.001) was seen following the bolus, there was overall
improvement in base deficit (p = 0.01) and plasma lactate
(p = 0.04) with a trend towards lower inotrope score. Serial
echocardiography revealed lower pulmonary artery pres-
sure, improved right and left ventricular output, and re-
duced bidirectional or right-left shunting (p < 0.05) after
milrinone treatment. No infants were withdrawn from the
study and there were no cases of intraventricular haem-
orrhage, electrolyte disturbances, abnormal liver or co-
agulation profiles, thrombocytopenia, need for ECMO
or mortality.
Clinical effects of milrinone in PPHN
In our centre (Rotunda Hospital, Dublin), infants with a
clinical diagnosis of PPHN who fail to respond to iNO
within 4 h of commencement undergo a comprehensive
echocardiogram to rule out congenital heart disease, as-
sess myocardial function and the degree of pulmonary
hypertension (PH). Those infants are then commenced
on milrinone in an attempt to augment iNO action and
improve myocardial performance. We conducted a re-
view of all infants undergoing this treatment over an
18-month period. The Rotunda Hospital Research Ethics
Committee approved this study [28].
This was a retrospective review of infants ≥34 weeks
gestation with PPHN who received milrinone. The pri-
mary end point was the effect of milrinone on RV and
LV function parameters including right (RVO) and left
(LVO) ventricular outputs, tissue Doppler velocities, RV
and septal strain and strain rate, tricuspid annular plane
systolic excursion (TAPSE) and LV myocardial performance
index (MPI). Secondary endpoints examined included dur-
ation of iNO and oxygen support, change in blood pressure,
and the use of cardio-respiratory support.
Seventeen infants with a mean (SD) gestation and birth
weight of 39.8 (2.0) weeks and 3.45 (0.39) Kg respectively
were included. All infants received iNO within 3 h of birth.
The median duration of invasive ventilation for the cohort
was 5 [5–8] days. The median hospital stay in the tertiary
NICU was 12 [11–16] days. One infant died before dis-
charge (35 5/7 weeks gestation, polycystic kidney disease,
prolonged anhydramnious and hypoplastic lungs). None of
the infants required ECMO. The cohort underwent the first
echocardiogram 15 [8–28] hours after iNO commence-
ment. Milrinone was started at a median time of 1 [0.5–3]
hour after the echocardiogram, 17 [9–34] hours after iNO
treatment. The median [range] starting dose was 0.50 [0.3–
0.66] μg/kg/min. Most infants remained on the median
dose for the duration of the treatment with the exception
of one infant requiring an escalation to 0.66 μg/kg/min and
two up to 0.75 μg/kg/min. The median duration of treat-
ment was 88 [65–118] hours.
Milrinone administration was associated with an increase
in LVO (p = 0.04), RVO (p = 0.004), RV strain (p = 0.01) and
strain rate (p = 0.002), and LV s` (p < 0.001) and a` (p =
0.02) tissue Doppler velocity waves. There was a significant
reduction in iNO dose, oxygen requirement over the subse-
quent 72 h (all p < 0.05). In addition, the administration of
milrinone was associated with a reduction in mean blood
pressure (p = 0.04) peaking at 6 h post administration. This
was associated with a significant increase in the use of vaso-
active inotropes at 6 and 24 h. However, blood pressure
began to increase after 12 h of milrinone administration
with a peak at 72 h (systolic BP p = 0.02, mean BP p = 0.03,
diastolic BP p = 0.02) in spite of a reduction in the use of
vasoactive inotropes over the same time period.
Rationale for milrinone use
PPHN is common and leads to a major burden of neo-
natal illness, carries a significant mortality, need for
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ECMO, and adverse neurodevelopmental outcome.
There is poor appreciation of the physiologic determi-
nants of PPHN and predictors of iNO response at pres-
entation; up to 40% of infants do not respond to iNO
treatment. The increasing cost of iNO may preclude its
use in both the developed and developing countries. The
use of milrinone in infants with PPHN as an adjunct to
iNO is worth further exploration with preliminary evi-
dence suggesting an improvement in both oxygenation
and myocardial performance in this group of infants. It’s
inotropic, lusitropic and pulmonary vasodilator proper-
ties make it an ideal agent to use in this setting and may
improve response to therapy and reduce mortality asso-
ciated with the disease.
A recent Cochrane review illustrated the lack of ran-
domised controlled trials (RCTs) comparing the use of
milrinone versus placebo or as an adjunct to iNO com-
pared with iNO alone in the setting of PPHN and rec-
ommended limiting the use of milrinone in PPHN to the
research setting [29]. It is important to systematically in-
vestigate the efficacy of milrinone in the setting of PPHN
prior to widespread dissemination of this treatment.
Objectives
Primary objective
We hypothesize that intravenous milrinone used in con-
junction with iNO results in the reduction in the time
on iNO therapy and the time spent on invasive ventila-
tion in infants ≥34 weeks gestation and ≥ 2000 g with a
clinical and echocardiography diagnosis of PPHN.
Secondary objective
The aim is to compare: the incidence of the use of other
inotropes; critically low LV and RV function and output
measured by echocardiography and a non-invasive cardiac
output monitor (NICOM); the rate of adverse effects
associated with milrinone including the incidence of
hypotension; and the pre-discharge outcomes in the
two groups. In this pilot study, we aim to assess the practi-
cality of instituting the protocol and contributing to a
sample size calculation for a definitive multicentre study.
Trial design
This is a multicentre, randomized, double-blind, two
arm pilot study, with a balanced (1:1) allocation that will
be carried out in the level III neonatal intensive care
units in 2 centres in Ireland: The Rotunda Hospital
Dublin and Cork University Maternity Hospital, and one
centre in the Netherlands: Radboudumc Amalia Children’s
Hospital, Nijmegen (Fig. 1).
The relevance of the primary outcome
iNO use is expensive and currently requires invasive venti-
lation. Invasive ventilation can cause baro- and volutrauma,
may lead to parenchymal lung damage and the evolution of
pneumothoraces. Ventilation is often accompanied by the
administration of sedative agents such as morphine and
midazolam. In addition, prolonged ventilation will delay
bonding with parents, delay feeding and suckling and will
lead to prolonged hospitalisation. A reduction in the time
spent invasively ventilated will (in addition to the other
benefits outlined above) reduce hospital stay, promote
earlier enteral nutrition, parental bonding, breast feeding
and significantly reduce healthcare costs.
The purpose of this pilot study is to assess the feasibility
of performing a pivotal trial and to obtain preliminary data
to calculate a sample size for a definitive multi-centre trial
of milrinone therapy in PPHN. We aim to recruit a total
of 20 infants with PPHN (10 receiving milrinone and 10
receiving placebo) over a 4-year period. We then plan to
seek additional funding in order to facilitate the running
of the multicentre RCT in European and North American
centres. In this pilot study we also aim to ascertain issues
with recruiting infants and obtaining consent, compliance
with the protocol, the rate (if any) of loss to follow up, and
the general acceptability, feasibility and compliance of
administering the intervention. This number will also
allow us to calculate a standard deviation which will be
used in a sample size calculation for the full-scale trial. In
addition, we aim to refine the criteria for discontinuing
therapy which are outlined below.
Methods
Participants interventions and outcomes
Setting
This feasibility study will be conducted in three Level III
neonatal intensive care units (NICU). Two in Ireland:
The Rotunda Hospital, Dublin, and Cork University
Maternity Hospital; and one in the Netherlands:
Radboudumc Amalia Children’s Hospital, Nijmegen.
Eligibility criteria
All infants with a gestation ≥34 week and a birth
weight ≥ 2000 g admitted to the neonatal intensive care
unit with a clinical diagnosis of PPHN and commenced
on iNO will be deemed potentially eligible for this study.
The process of iNO initiation in PPHN on clinical
grounds and is standardised in the NICUs and is de-
tailed in Additional file 1. The decision is made by the
attending physician. In addition; the infants must satisfy
the following criteria:
1) ≤ 10 postnatal days of life and within 4 days of
admission
2) Echocardiography diagnosis of PPHN (see below)
3) Absence of significant congenital heart defect
excluding a small atrial septal defect or ventricular
septal defect (measuring less than 3 mm)
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4) Oxygenation index of ≥10 measured obtained from
an arterial blood sample and calculated using the
following formula: OI = (Mean airway pressure ×
FiO2 × 100) ÷ (paO2 in kilopascals)
Exclusion Criteria
1) Lethal congenital anomalies or obvious syndrome
2) Bleeding diathesis (abnormal coagulation screen/
platelet < 100,000/ mm3)
3) The presence of Intraventricular haemorrhage.
4) Diastolic Hypotension (defined as a diastolic blood
pressure less than the 3rd centile for any given
gestation) unresponsive to medical treatment
(≥30 mL/kg fluid bolus and ≥ 2 inotropes)
5) Hypoxic-ischemic encephalopathy undergoing
therapeutic hypothermia
6) Evidence of renal impairment (Creatinine >100
micromol/l)
7) Severe Hypovolaemia: Heart rate > 180, capillary
refill > 5 s, urine output < 0.5 ml/kg/hour, in
addition to diastolic hypotension mentioned above.
Intervention
Infants in the intervention arm will receive an intravenous
loading dose of milrinone lactate injection (10 mg/10 mL)
at a dose of 50 μg/kg administered over 60 min followed
by a maintenance infusion, beginning at 0.375 μg/kg/min
to a maximum 0.750 μg/kg/min. The duration of therapy
is until discontinuation of iNO or a maximum of 35 h in
adherence with the summary of product characteristics
(SmPC) recommendation. A 10 mL/kg bolus of normal
saline will be administered with the milrinone bolus over
the same 1 h period.
A loading dose was chosen to ensure the rapid attain-
ment of therapeutic blood concentrations. The slow rate
of administration was chosen to minimize the risk of
infusion-related adverse effects, such as hypotension. This
dosing regimen was established following the recent phar-
macokinetic study performed by our group and described
above [27]. Dose increase will be performed in response to
the need for oxygen (FiO2) to maintain adequate
pre-ductal saturations (95% or greater). Dose incrementa-
tion will be carried out every 2 h following the bolus if the
fall in FiO2 needed to maintain an adequate saturation is
less than 20%. Dose escalation will be carried out as de-
scribed below (Section “Product and placebo preparation
and infusion regimen”). For example, if 2 h after adminis-
tration, the FiO2 of an infant falls from 60 to 45% (< 20%)
to maintain a saturation of 95% or greater, the rate of infu-
sion will be increased based on the table below. This escal-
ation will continue every 2 h until a reduction of FiO2 of
20% or greater is achieved down to 40% FiO2. The max-
imum dose will be 0.750 μg/ kg/min.
Control
Infants in the control arm will receive an intravenous
loading dose of placebo (normal saline) at a rate equiva-
lent to the infusion rate of the milrinone bolus, adminis-
tered over 60 min. A bolus of normal saline of 10 ml/kg
will accompany the placebo infusion, as per the inter-
vention arm. Following the loading protocol, a saline in-
fusion running at a rate similar to the milrinone infusion
will be commenced for a maximum period of 35 h or
Fig. 1 Trial Schematic
EL-Khuffash et al. Maternal Health, Neonatology, and Perinatology            (2018) 4:24 Page 5 of 12
until discontinuation of iNO if it occurs sooner. The
saline infusion will be titrated up in increments similar
to the milrinone infusion.
Product and placebo preparation and infusion regimen
The proposed placebo is an authorised product in the
EU- see PA below.We will prepare the product in line
with the instructions in the SPC. The outline below will
be included in the protocol as suggested. The product
will be diluted with solutions specified in section 6.6 of
the SPC. A milrinone infusion solution containing 200
micrograms/ml will be prepared by diluting 10 ml of
Primacor injection with 40 ml of 0.9% sodium chloride
(Baxter Sodium Chloride 0.9% w/v Intravenous Infusion
BP 100 ml- PA 0167/008/015). The syringe will be
inverted at least 10 times to ensure adequate mixing. Each
infusion syringe will be freshly prepared before use. The
prepared infusion will be visually inspected for particulate
matter or discolouration. The diluted solution will be used
within 1 h of preparation.
The placebo infusion will consist of 50 ml of the diluent
(Baxter Sodium Chloride 0.9% w/v Intravenous Infusion
BP 100 ml- PA 0167/008/015). Each placebo infusion
syringe will be freshly prepared before use. The prepared
placebo infusion will be visually inspected for particulate
matter or discolouration. Administration rates will be
guided by the SPC:
Use of additional inotropic and concomitant therapy
The most common co-morbidity accompanying pulmonary
hypertension in term infants is hypotension. The approach
to managing systemic hypotension will be as follows:
 Systolic hypotension (defined as a systolic BP < the
3rd centile for any given gestation) will be treated
with a bolus of saline (10 ml/kg) followed by adrenaline
at a dose of 0.05 μg/kg/min up to 2 μg/kg/min.
 Diastolic hypotension (defined as a diastolic BP < the
3rd centile for any given gestation) will be treated
with a bolus of saline (10 ml/kg) followed by
dopamine at a dose of 5 μg/kg/min up to a
maximum of 20 μg/kg/min.
Infants failing to respond to the above interventions
will be withdrawn from the study and un-blinded (see
below). Dobutamine will not be used during the study
period due the risk of hypotension when used concomi-
tantly with milrinone. Adrenaline/noradrenaline will be
used as second line agents. Steroids will be used for severe
hypotension/shock at a dose of 1 mg/kg 6 hourly IV.
If required, infants will be sedated with fentanyl (rather
than morphine) to avoid the risk of hypotension. The
starting dose of the fentanyl infusion is 1.0 μg/kg/min
following a bolus of 1.0 μg/kg. Management of all other
aspects of pulmonary hypertension will be at the discre-
tion of the attending neonatologist based on unit policies.
Other pulmonary vasodilator agents such as sildenafil,
prostacyclin and/or bosentan will not be used during the
study period.
Other considerations:
 Aminophylline/Caffeine: aminophylline/caffeine may
compete with milrinone for phosphodiesterase
inhibition and therefore may attenuate the clinical
effect. However, aminophylline/caffeine
administration is not used in infants with PPHN and
therefore the risk of co-administration is low. None-
the-less, we will exclude patients with concomitant
administration from the study.
 Frusemide or bumetanide will not be administered
in intravenous lines containing milrinone lactate in
order to avoid precipitation.
 Milrinone will not be diluted with sodium bicarbonate.
 As outlined below in the monitoring section
(Monitoring, outcome measures and participant
timeline): hypokalaemia will be monitored and
corrected in advance of/and during milrinone use as
diuresis secondary to improved cardiac output may
ensue following milrinone administration.
 Calcium channel blockers (CCB) are not used in
neonates and therefore the potential interaction
between milrinone and CCBs is not a concern in
this study.
Exit criteria
The following criteria will mandate the discontinuation of
the intervention in both arms and a return to standard of
care, as these are considered side effects of the medication
if they occur within 1 to 3 days of administration of the
medication: profound hypotension requiring > 30 mL/kg
fluid bolus and inotropic support of ≥20 mcg/kg/min of
intravenous dopamine or dobutamine, thrombocytopenia
of ≤100,000/mm3, and arrhythmia requiring treatment.
Randomisation and allocation
A computer-generated central randomisation scheme
will be used to assign the infants to the two arms in a
Primacor Injection Dose
(μg/kg/min)
Infusion Delivery Rate
(ml/kg/hr)
0.375 0.11
0.400 0.12
0.500 0.15
0.600 0.18
0.700 0.21
0.750 0.22
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1:1 ratio. Each infant will be assigned a unique 3 digit
identification (ID) number. The study pharmacist in
each centre will receive a binder containing the se-
quence of treatment group assignments for the cohort
from a statistician who will not otherwise be involved
in the study. At each study center, access to the binder
will be restricted to selected pharmacy personnel, and
will be kept locked in a secure locker in the pharmacy
department.
Concealment and blinding
Both formulations are clear and colourless. The ampoules
used will be identical and will have a study identification
number included in the label on the ampoule. This number
will be known to the study pharmacist. Once a patient is
recruited and randomised to either Milrinone or Placebo,
the trial pharmacist or physician not involved in recruit-
ment, allocation, and data collection will prepare the trial
drug or placebo and issue the syringe for infusion to the
trial investigator team for administration. An on call
arrangement will be devised for out of hours preparation.
The milrinone preparation is colourless and odorless and
will be indistinguishable from the saline preparation used
for the placebo arm. The designated pharmacist in each
study centre will be aware of the treatment allocation in
order to facilitate correct assignment and drug/placebo
preparation. The trial participants and their families, the
care providers, the data collectors, the echocardiographers,
the primary outcome assessors, and the data analysts will
all be blinded to the allocation.
Monitoring, outcome measures and participant timeline
The primary outcome of this study is the time on iNO in
hours and the time on invasive ventilation. A standardised
protocol for iNO weaning is detailed in Additional file 2.
We will collect the following demographic characteristics
and relevant short-term secondary outcomes: duration of
hospital stay; time to extubation; duration of oxygen ther-
apy, and survival.
Details of cardiorespiratory stability (blood pressure,
heart rate, oxygen saturation), ventilation support (FiO2,
mean airway pressure (MAP), oxygenation index [MAP × F
FiO2/PaO2]), efficacy of oxygenation [PaO2], plasma lactate,
pH, PCO2, HCO3
−, Base excess; and relevant co-treatments
(i.e., sedation, analgesics, muscle relaxants, inotropes, fluid
administration) at the following time points:
1) Prior to treatment
2) Following the loading dose
3) 12 h after initiation of therapy
4) 24 h after initiation of therapy
5) Two hours after discontinuation of therapy
Monitoring of blood parameters will be carried out
as follows during the study period and 24 h after drug
discontinuation:
 Full blood count (including platelets): daily
 Electrolytes, Urea and Creatinine: daily
 Liver function tests (ALT, AST, GGT): daily
 Blood gas analysis: 12 hourly
Echocardiography will be performed according to the
following schedule: a timing window of ±3 h will be ap-
plied. Scans performed outside the ±3 h window will
constitute a protocol deviation:
1) Prior to the Commencement of Study Drug:
Diagnose PPHN and rule out CHD
2) 12 h following the administration of Study Drug
3) 24 h following the administration of the study drug
4) 8 h following the discontinuation of the study drug
Non-invasive Cardiac output Monitoring (NICOM)
will be commenced prior to the commencement of the
study drug and continued until the last echocardiogram,
8 h after the discontinuation of the study medication.
Cranial ultrasound will performed prior to treatment
commencement and after the discontinuation of the in-
fusion. Intraventricular haemorrhage will be defined and
graded with the Papile classification [30]. Echocardiog-
raphy will be carried out at baseline as detailed above
and at 12 h, 24 h, 2 h after discontinuation of therapy,
and before discharge.
Echocardiography assessment of PPHN
All infants will undergo a comprehensive echocardiog-
raphy assessment at baseline prior to enrollment to rule
out congenital heart disease, quantify the magnitude of
pulmonary hypertension and assess left and right ven-
tricular output and function. The functional protocol for
the echocardiography assessment is adapted from the re-
cent American Society of Echocardiography Guideline
on neonatal echocardiography [31, 32]. All infants will
be assessed once established on iNO and are in a quiet
state using the Vivid E9 or the Vivid S6 (GE Medical,
Milwaukee, WI, USA) and a 10 Mhz transducer. A diag-
nosis of PPHN will be made if any of the following is
identified in the absence of cyanotic congenital heart
disease:
 A tricuspid regurgitant jet with a pressure gradient
≥2/3 systemic systolic blood pressure
 Intra-ventricular septum flattening or bowing into
the left ventricular cavity
 Patent ductus arteriosus bidirectional shunting or
predominant right to left shunting
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 A pulmonary artery acceleration time < 40 milliseconds
We will collect the following parameters at the same
time points outlined in section “Monitoring, outcome
measures and participant timeline”:
Assessment of pulmonary Hypertension: PDA Shunt
Direction; Pulmonary artery acceleration time (PAAT);
Right ventricular ejection time (RVET); PAAT:RVET
ratio; Tricuspid regurgitant jet pressure gradient;
Interventricular septum motion in systole.
Assessment of RV performance: Right ventricular tissue
Doppler velocities, strain and strain rate; Right
ventricular output (RVO); Right ventricular TAPSE
(Tricuspid Annular Peak Systolic Velocity); Right
ventricular dimensions; Right ventricular fractional area
shortening.
Assessment of LV performance: Shortening fraction;
Ejection fraction measured by Simpson’s biplane
method; Tissue Doppler velocities; Left ventricular
strain and strain rate; Left ventricular output (LVO);
Left ventricular twist, and twist/untwist rate.
Assessment of Pulmonary venous return; Left atrial to
aortic root ratio; Pulmonary vein peak systolic and
diastolic velocity; Mitral valve E and A velocities, E:A
ratio, and mitral value VTI, IVRT; The presence of
PFO/ASD and the velocity of the shunt.
Assessment of PDA parameters: PDA size in 2D
measured at the pulmonary end, mid ductal and aortic
end; the direction and peak velocity of flow across the
shunt; Pressure gradient across the shunt.
Markers of systemic hypoperfusion: Abdominal aortic
peak systolic velocity and diastolic flow direction and
velocity; Celiac artery peak systolic velocity and
diastolic flow direction and velocity; Middle cerebral
artery peak systolic velocity and diastolic flow direction
and velocity.
Reliability analysis was recently conducted and ascer-
tained normative data for all the above-mentioned
echocardiography parameters in 50 healthy term infants.
Acceptable reliability was demonstrated in measuring all
the functional parameters. In addition, the reference ranges
and the effect of physiological postnatal transition is de-
scribed [33].
Slow closure of the patent ductus arteriosus is a theoret-
ical risk in association with the use of milrinone due to
the drug’s vasodilatory properties. However, in our obser-
vational study of 17 infants (section 1.2.3), none had a pa-
tent ductus arteriosus by the time of discharge despite the
relatively longer duration of milrinone use in the observa-
tional study (median of 88 h). We will assess the presence
of patent ductus arteriosus before discharge on all infants
enrolled to further study this association.
Non-invasive cardiac output assessment (NICOM)
Non-invasive cardiac output monitoring has gained interest
in the assessment of neonatal haemodynamics [34, 35].
Trans-thoracic bioreactance is a new technique of non-in-
vasive continuous cardiac output monitoring. It is based on
an analysis of relative phase shifts of oscillating currents
that occur when an injected current traverses the thoracic
cavity. The system’s signal processing unit determines the
relative phase shift (Φ) between the input and output sig-
nals. Stroke volume (SV) can be estimated by: SV =C x
VET x dΦ/dtmax, where C is a constant of proportionality,
VET is ventricular ejection time (determined from the
NICOM and ECG signals) and dΦ/dtmax is the peak rate
of change of Φ.
The value of C has been optimized in prior studies
and accounts for patient age, gender and body size. SV
and left ventricular (LVO) measurement are provided in
60 s intervals [36]. In the adult population, NICOM has
acceptable accuracy and precision for cardiac output
monitoring in patients with hemodynamic instability
when compared to thermodilution, aortic artery cath-
eterisation, and cardiopulmonary bypass pumps [36–38].
Recently, NICOM was compared to echocardiography
measures of LVO in a cohort of near term and term ne-
onates with acceptable reliability and precision [35]. In
addition, NICOM has the ability to identify different
haemodynamic patterns and response to milrinone ad-
ministration in preterm infants following PDA ligation
[35]. These properties suggest that NICOM may be an
ideal device for the assessment of the haemodynamic
profile of infants with PPHN.
Continuous LVO measurement using bioreactance is
facilitated by the NICOM system. The measurement will
take place during the entire study period. Bioreactance is
the analysis of the variation in the frequency spectra of a
delivered oscillating current when it traverses the thor-
acic cavity. This is obtained by placing four emitting and
receiving electrodes in a manner that “boxes” the heart.
Each electrode sensor strip consists of two contact
points. Upper thoracic electrode strips will be placed
over the mid-clavicles and upper back bilaterally. The
lower electrode sensors are placed between the 6th and
7th intercostal spaces at the mid-axillary line. The elec-
trode set will be replaced after 48 h of measurement to
ensure adequate signal acquisition. NICOM measure-
ment of SV and LVO will be blinded to the echocardiog-
raphy and the clinical team by covering the screen
displaying the values. The echocardiographic measure-
ment of SV and LVO will be paired with the correspond-
ing NICOM readings following study completion. The
NICOM system stores each reading of SV and LVO.
SVR will be measured by the NICOM system on an
hourly basis as the mean blood pressure is entered into
the machine.
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Data management and statistical analysis
Sample size
This study is conducted to determine the feasibility of
patient recruitment, instituting the study protocol, ran-
domising and blinding allocation, collecting outcome
data and contribute to determine the sample size neces-
sary for a definitive multicentre trial. A sample of 10 in-
fants per arm (a total of 20 infants) will be recruited
over a 4-year period.
Recruitment strategies
The recent incidence of pulmonary hypertension in the
three study sites is 1–2 per 1000 live births. The total
annual birth rate in the 3 centres is around 24,000 giving
24–48 potential eligible infants. The rate of moderate to
severe PH in this cohort (fulfilling the eligibility criteria)
will be around 50% (12–24 infants per annum). We an-
ticipate a 50% to 75% enrolment rate per year to account
for consent refusal, competition with other studies and
unavailability of staff to recruit patients. Therefore, we
anticipate a recruitment period of 4 years. All centres
are experienced in the conduct of clinical trials. They
also have the expertise to carry out the assessment of
the primary and secondary outcomes and to perform the
echocardiography and NICOM assessments. We do not
anticipate any variability in administering the interven-
tion between sites over time.
Data management
Clinical and demographic data, as well as outcome data
will be collected by the research fellows at each site who
will be blinded to treatment allocation. Pilot testing of
the data collection sheet will be performed prior to study
commencement. No patient identifiers will be used and
each patient will be assigned a unique ID number based
on the sequence in recruitment. The data sheets will be
stored in a designated secure locker with access granted
only to the research fellows and principal investigators.
Echocardiography data will be stored on secure hospital
servers. Off-line analysis of the echocardiography data
will be performed and image analysis techniques will be
standardised. The investigators analysing the study will
be blinded to the allocation.
Statistical methods
The HRB IP CTN clinical trial statistician will conduct
all the statistical analyses. The primary outcome and
most of the secondary outcomes are continuous vari-
ables. Continuous variables will be tested for normality
by comparing the mean and median, a histogram repre-
sentation of data, and the Shapiro-Wilk test for normal-
ity and will be presented as means (standard deviation)
or median [inter-quartile range] as appropriate. Dichot-
omous variables will be presented as proportions and
summarised in contingency tables. The primary analysis
of the primary outcome will be performed using an inde-
pendent t-test (or a Wilcoxon Rank Sum test as appro-
priate) to compare the difference in time on iNO and
invasive ventilation between the two groups. A chi
squared test (or Fisher’s exact test) will be used for the
primary analysis of the dichotomous secondary out-
comes. For the continuous secondary outcomes, a t-test
will be used to compare normally distributed data, and
Wilcoxon Rank Sum test will be used for skewed data.
We will accept a p value of < 0.05 as significant. We will
use SPSS (version 22) to perform the statistical analysis.
All enrolled infants will be analysed on an intention-
to-treat basis, including infants that have not continued
treatment for any reason. Analysis for the feasibility study
will only be conducted once the recruitment of all patients
is completed. No interim analysis of treatment effect will be
conducted. We anticipate that recruitment will take 4 years
to complete with an additional 6 months required for the
measurement of the echocardiography data and statistical
analysis.
Data monitoring and managing adverse effects
The study will be registered online at EUDRACT. The
day-to-day management of the study will be coordinated
by a designated research fellow at each study site. The
research team in each site will consist of the following
personnel: Principal investigator with echocardiographic
skills designated study pharmacist for drug preparation;
research fellow for consent, infant enrolment and data
collection.
A Trial Management Committee (TMC) will be set up
to include the lead Principal Investigator, HRB IP CTN
statistician, Quality and Regulatory Manager and Trial
coordinator. This committee will be responsible for: in-
tegration of the study protocol into the clinical setting;
training of the various study personnel; adherence to
study protocol; maintenance of concealment and adequate
randomisation. In addition, the TMC will oversee data col-
lection and ensure completeness, validity, and track recruit-
ment rates in the various sites in collaboration with the
Trial Sponsor (The Royal College of Surgeons in Ireland)
Data checks will include assessment of the presence of
missing or invalid data.
The conduct of this study will conform to the ICH
Harmonized Tripartite Guideline for Good Clinical Prac-
tice. An independent Data Monitoring Committee (DMC)
will be convened and consist of 2 external neonatologists
and a statistician. This will be independent from the spon-
sor (The Royal College of Surgeons in Ireland) and from
competing interests. The role of this committee will con-
sist of monitoring the emergence of adverse effects and
any unexpected hazards.
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Ethics, dissemination
Ethical approval will be sought from the local research
ethics committees at all centres. HPRA approval for the
use of milrinone in PPHN will be sought prior to com-
mencement of the study and any amendments to the
protocol will be submitted to both the HPRA and the re-
search ethics committee. The Dutch site will seek local
regulatory body approval in the Netherlands.
The local PI will initially approach the physician re-
sponsible for the care of the infant for permission to ap-
proach the parents with a view to informing them of the
pilot study. All parents will be provided with a clear ex-
planation of the objectives, procedures, risks and bene-
fits of the study in the Parent Information Leaflet. The
investigator must provide time and opportunity for them
to ask questions and ascertain details of the study. Fur-
ther information will be given verbally and all questions
will be answered. Parents will be given 6 h to consider
enrolment into the study. Once all discussions are com-
pleted they will be invited to sign the consent form.
Informed consent will be obtained before any study as-
sessments/procedures are performed and before any data
collection occurs. All personal study participant data col-
lected and processed for the purposes of this study will be
managed by the investigators and their staff with adequate
precautions to ensure the confidentiality of those data and
in accordance with applicable national and local laws and
regulations on personal data protection. The ethics com-
mittees approving this research will be granted direct ac-
cess to the study participants’ original medical records for
verification of clinical trial procedures and/or data, with-
out violating the confidentiality of the participants, to the
extent permitted by the law and regulations.
No patient identifiers will be used during data collec-
tion or analysis of the study. No individual patient data
will be presented. All data will be presented summarized
as means, medians, or proportions as appropriate. Pa-
tients will be allocated a unique number based on site
and enrolment number. Parents are free to withdraw
their infants from the research study at any stage. Data
will be stored in an encrypted secure computer in a
locked office in the department of Paediatrics.
The results of the study will be shared with all partici-
pant families. In addition, they will be presented at all the
participating hospitals’ grand rounds. Data will be pre-
sented at the Annual Pediatric Academic Society Meeting
for mass dissemination of the results. Submission for pub-
lication to a peer reviewed journal of a high impact factor
will also be sought.
Conclusion
Significant savings for the health service
A positive outcome in this pilot study will pave the way
for a definitive trial of the use of milrinone for the
treatment of PPHN. Improving the response rate to iNO
and reducing the time on iNO and mechanical ventila-
tion will have substantial short and long-term benefits
for the healthcare service. Reduced length of stay will
significantly reduce hospital costs in the neonatal intensive
care unit. In addition, iNO administration is expensive (up
to €50 per hour). Milrinone is relatively cheap costing
about €30 per patient. There is potential for substantial
savings if the use of milrinone is successful in reducing
time on iNO. The increasing cost of iNO may soon pre-
clude its use in both developed and developing countries
so this study is urgently needed.
Reducing burdens on families
Improving the response rate to iNO, reducing the time
on iNO and mechanical ventilation will have substantial
short and long-term benefits for the infants and their
families. Reducing hospital stay, improving the response
rate and reducing the chance of undergoing ECMO will
improve the quality of life of the infant, facilitate earlier
nutrition and discharge, and potentially improve neuro-
developmental outcome.
A greater understanding of the pathophysiology of PPHN
PPHN is a common occurrence in neonates and leads to
a major burden of illness, carries a significant mortality,
a need for ECMO, and adverse neurodevelopmental out-
come. There is poor appreciation of the physiologic de-
terminants of PPHN and predictors of iNO response at
presentation with up to 40% of infants not responding to
iNO treatment. The echo and NICOM measurements
performed in this study will provide evidence both on
the pathophysiology of PPHN but also on the efficacy of
milrinone therapy.
Establishing Ireland as a recognised leader in cardiovascular
support
This pilot study will be the first randomised controlled
trial to evaluate milrinone use in term infants with pul-
monary hypertension. This study, along with another HRB
IP CTN trial - the HIP Trial which evaluates blood pres-
sure support in preterm infants, again the first of its kind,
will establish Ireland’s neonatal community as world
leaders in the area of newborn cardiovascular support.
Additional files
Additional file 1: Commencement of iNO in infants with PPHN.
(DOCX 39 kb)
Additional file 2: Weaning iNO. (DOCX 43 kb)
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